Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Anatomic Stage IV Breast Cancer AJCC v8 · HER2-Negative Breast Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Principal Investigator (Margaret E. Gatti-Mays, MD, MPH)
Study leads
Margaret E Gatti-Mays, MD MPH
Principal Investigator
Ohio State University Comprehensive Cancer Center